Article
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2006
Ouyang Bin, Knauf Jeffrey A, Smith Eric P, Zhang Lei, Ramsey Tim, Yusuff Naeem, Batt David, Fagin James A
Abstract excerpt
PURPOSE: Papillary thyroid carcinomas are associated with nonoverlapping activating mutations of RET, NTRK, RAS and BRAF, which altogether are present in approximately 70% of cases. We postulated that compounds that inhibit a distal effector in the mitogen-activated protein kinase (MAPK) pathway would inhibit growth and tumorigenicity of human thyroid cancer cell lines with mutations of RET or BRAF. EXPERIMENTAL...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.